

BIO-TECHNE Corp  
 Form 4  
 August 11, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**VERONNEAU MARCEL**

(Last) (First) (Middle)

614 MCKINLEY PLACE N.E.

(Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**BIO-TECHNE Corp [TECH]**

3. Date of Earliest Transaction (Month/Day/Year)  
**08/07/2015**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)

SVP - Clinical Controls

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock				(A) or (D) Price	34,913	D	
Common Stock				(A) or (D) Price	6,827	I	by Stock Bonus Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

Edgar Filing: BIO-TECHNE Corp - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 62.46					<u>(1)</u>	07/23/2016	Common Stock	494
Stock Option (Right to Buy)	\$ 66.25					<u>(1)</u>	04/29/2017	Common Stock	10,000
Stock Option (Right to Buy)	\$ 58.4					<u>(1)</u>	07/29/2017	Common Stock	1,281
Stock Option (Right to Buy)	\$ 76.15					<u>(1)</u>	07/27/2018	Common Stock	20,000
Stock Option (Right to Buy)	\$ 76.15					<u>(1)</u>	08/27/2018	Common Stock	1,129
Stock Option (Right to Buy)	\$ 74.05					<u>(1)</u>	07/26/2019	Common Stock	1,097
Stock Option (Right to Buy)	\$ 76.02					<u>(2)</u>	07/31/2020	Common Stock	15,000
Stock Option (Right to Buy)	\$ 94.35					<u>(3)</u>	08/12/2021	Common Stock	15,000

Stock Option (Right to Buy)	\$ 108.49	08/07/2015	A	7,500	<u>(4)</u>	08/07/2022	Common Stock	7,500
Stock Option (Right to Buy)	\$ 108.49	08/07/2015	A	3,750	<u>(6)</u>	08/07/2022	Common Stock	3,750
Restricted Stock Units	<u>(5)</u>	08/07/2015	A	600	<u>(6)</u>	<u>(6)</u>	Common Stock	600

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
VERONNEAU MARCEL 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413			SVP - Clinical Controls	

## Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for Marcel Veronneau pursuant to Power of Attorney filed herewith.

08/11/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Fully exercisable.

(2) Vests 3,750 shares on each of 8/1/14, 8/1/15, 8/1/16, and 8/1/17.

(3) Vests 3,750 shares on each of 8/12/15, 8/12/16, 8/12/17, and 8/12/18.

(4) Vests 1,875 shares on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

(5) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(6) Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.